About: http://data.cimple.eu/news-article/033292b04eaa92ed127732e1e0e8d3b5256f883ff23e12b6da7f3cf2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/033292b04eaa92ed127732e1e0e8d3b5256f883ff23e12b6da7f3cf2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Swiss pharmaceutical giant Roche on Thursday posted a steep hike in 2019 net profit, boosted by strong sales of new treatments, which offset stark challenges facing the company's previously top-performing cancer drugs. The world's largest maker of cancer drugs raked in a net profit last year of 14.1 billion Swiss francs ($14.5 billion, 13.2 billion euros), marking a 30-percent-hike compared to 2018. Roche meanwhile reported sales up eight percent at 61.4 billion Swiss francs, amid particularly strong results for its multiple sclerosis medicine Ocrevus and haemophilia drug Hemlibra, along with cancer medicines Tecentriq and Perjeta. The company also hailed the "strong uptake" of newly introduced medicines, which brought in sales of 5.4 billion francs. This more than offset the blow dealt by growing so-called biosimilars competition, after patents on several of its top-performing cancer treatments, including MabThera/Rituxan and Herceptin, expired. In Europe and Japan alone, those drugs were hit by a 1.2-billion-franc decline in sales last year, Roche said. Company chief Severin Schwan was upbeat about what he described as "excellent operating results". "Based on the progress made in rejuvenating our portfolio, Roche is very well positioned to grow going forward," he said in a statement. Schwan said the company expected to see sales growth of between one and five percent, "in spite of the even greater impact of the competition from biosimilars." Following the news, Roche saw its share price inch up 0.25 percent to 326.40 Swiss francs in mid-morning trade as the Swiss stock exchange's main SMI index slipped 0.74 percent. noo/nl/bmm
schema:headline	Roche sees net profits rise by a third in 2019
schema:mentions	Multiple sclerosis Hoffmann-La Roche Pharmaceutical industry Medication Switzerland Cancer European Union Pertuzumab Severin Schwan Atezolizumab Haemophilia Trastuzumab Rituximab Biosimilar Economy of Japan
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-01-30 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	61 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software